- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07715656
Assessing Outcomes of Coil Embolization for Unilateral vs Bilateral Chronic Subdural Hematomas ((COAST))
Assessing Outcomes of Coil Embolization for Unilateral vs Bilateral Chronic Subdural Hematomas: A Randomized Controlled Trial.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Sandy L Alvarez, MD
- Número de teléfono: 7865800186
- Correo electrónico: sandy.l.alvarez@lahey.org
Ubicaciones de estudio
-
-
Massachusetts
-
Burlington, Massachusetts, Estados Unidos, 01803
- Reclutamiento
- Lahey Hospital & Medical Center
-
Contacto:
- Kimberly Silverman
- Número de teléfono: 7817443330
- Correo electrónico: Kimberly.Silverman@lahey.org
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
Candidates for this study must meet ALL of the following criteria:
- Subject is 18 years of age or older.
- Subject has a diagnosis of chronic subdural hematoma with mass effect Determined by brain imaging (CT or MRI) and correlated clinical symptoms.
Pre-randomization modified Rankin Score (mRS) ≤3
a. Surgical Cohort: Assessment should reflect the subject's condition just prior to undergoing surgery. Assessment may be performed post-surgery using pre-surgical data.
Subdural Hematoma Size
Medical Management Cohort:
- Midline shift < 10mm and hematoma thickness > 10 mm as measured on coronal imaging perpendicular to the skull.
- No focal deficit related to the chronic subdural hematoma requiring surgical intervention
Surgical Cohort:
• No requirement
- A CT performed prior to randomization demonstrating stability of the hematoma. Stability is defined as no worsening of midline shift or increase in the size of the cSDH from the screening image that results in new or worsening clinical symptoms.
- Patient or designated Legal Authorized Representative, confirms the patient has the mental capacity, willingness and ability to comply with protocol and follow-up requirements
- In the opinion of the treating physician, MMA embolization is technically feasible, including evaluation of preoperative CTA, if available, or presence of a foramen spinosum bilaterally.
Exclusion Criteria:
Candidates will be excluded from participation if ANY of the following apply:
- Patients presenting with an acute SDH (e.g. patient with presenting with a SDH due to trauma); mixed density is permitted.
- Subject presents with bilateral cSDHs requiring treatment (contralateral cSDH <5mm and not requiring treatment is permitted.
- Subject presents with Glasgow Coma Scale < 9
- Markwalder assessment >4
- cSDH that developed with underlying conditions such as vascular lesions, brain tumor, arachnoid cyst, spontaneous intracranial hypotension, end stage renal disease (ESRD) on hemodialysis, end stage liver disease or other comorbidities causing a coagulopathy
- Prior carotid stent placement that crosses the origin of the External Carotid Artery (ECA) ipsilateral to the subdural hematoma
- Presumed septic embolus, or suspicion of microbial superinfection
- CT or MRI evidence of intra-cranial tumor or mass lesion
- Significant contraindication to angiography (eg. kidney failure).
- Life expectancy of less than 1-year
- Women who are pregnant, lactating, plan on becoming pregnant during the course of the clinical investigation. We routinely do pregnancy tests prior to this procedure, to avoid radiation exposure to the fetus including radiation on follow up CT scans
- Current involvement in an investigational (drug, device, etc.) clinical trial that may confound study endpoints. Subjects in observational, natural history, and/or epidemiological studies not involving intervention are eligible
- Patient unwilling to follow SOC recommendations (e.g. refuses surgery or lifestyle modifications)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Medical Management
In this cohort, subjects will undergo either unilateral or bilateral middle meningeal artery (MMA) embolization using coils as part of their medical management for chronic subdural hematoma (cSDH).
In the unilateral arm, the MMA on the side of the hematoma is embolized, while in the bilateral arm, both sides are embolized regardless of hematoma location.
|
In the bilateral approach, both middle meningeal arteries are accessed and embolized using coils, regardless of hematoma location.
Imaging guidance is used throughout the procedure to ensure proper coil placement, and post-procedure imaging confirms that both vessels are fully occluded.
In the unilateral approach, the middle meningeal artery (MMA) on the side of the hematoma is accessed via a catheter and occluded using coils under imaging guidance.
The procedure targets only the affected side, and follow-up imaging is used to confirm successful embolization and vessel occlusion.
|
|
Comparador activo: Surgical
In this cohort, subjects will undergo either unilateral or bilateral middle meningeal artery (MMA) embolization using coils in addition to standard surgical management for chronic subdural hematoma (cSDH).
In the unilateral arm, the MMA on the side of the hematoma is embolized, while in the bilateral arm, both sides are embolized regardless of hematoma location.
|
In the bilateral approach, both middle meningeal arteries are accessed and embolized using coils, regardless of hematoma location.
Imaging guidance is used throughout the procedure to ensure proper coil placement, and post-procedure imaging confirms that both vessels are fully occluded.
In the unilateral approach, the middle meningeal artery (MMA) on the side of the hematoma is accessed via a catheter and occluded using coils under imaging guidance.
The procedure targets only the affected side, and follow-up imaging is used to confirm successful embolization and vessel occlusion.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in cSDH Maximum thickness From Baseline on Non-contrast Head CT
Periodo de tiempo: Baseline, 1 month (3-6 weeks), and 3 months (10-14 weeks)
|
Change in maximum hematoma thickness (mm) and Volume (mL) measured on non-contrast head CT compared with baseline.
Measurements will be performed using standardized imaging review.
|
Baseline, 1 month (3-6 weeks), and 3 months (10-14 weeks)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants Requiring Additional surgical Intervention
Periodo de tiempo: Through 3 months
|
Number of participants requiring additional surgical treatment after randomization, including initial surgical evacuation in the medical management cohort or repeat hematoma evacuation in the surgical cohort.
|
Through 3 months
|
|
Change from Baseline in Modified Rankin scale (mRS) Score
Periodo de tiempo: Baseline, 1 month, and 3 months
|
Functional outcome measured using the Modified Rankin Scale (range 0-6).
change from baseline will be reported.
|
Baseline, 1 month, and 3 months
|
|
Number of participants with Procedure-related Serious Adverse Events
Periodo de tiempo: through 3 months after embolization
|
Number of participants experiencing procedure related adverse events, including but not limited to ischemic stroke, intracranial hemorrhage, arterial dissection, vessel perforation, access-site complications requiring intervention, or death.
|
through 3 months after embolization
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Jonathan Pace, MD, Lahey Hospital & Medical Center
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Trastornos cerebrovasculares
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Heridas y Lesiones
- Procesos Patológicos
- Enfermedad crónica
- Atributos de la enfermedad
- Hemorragia
- Trauma craneoencefálico
- Trauma, Sistema Nervioso
- Hemorragias intracraneales
- Hemorragia Intracraneal Traumática
- Condiciones Patológicas, Signos y Síntomas
- Hematoma Subdural
- Hematoma
- Hematoma Subdural Crónico
Otros números de identificación del estudio
- 20253018
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .